Last reviewed · How we verify
SCRI Development Innovations, LLC — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
1 Phase 3
5 Phase 2
3 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| RAD001 | RAD001 | marketed | ||||
| CVP | CVP | marketed | Combination chemotherapy regimen | Oncology | ||
| Ixabepilone (Ixempra) | Ixabepilone (Ixempra) | phase 3 | Microtubule-stabilizing agent | β-tubulin | Oncology |
Therapeutic area mix
- Oncology · 3
- Inflammation · 1
- Other · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Alliance for Clinical Trials in Oncology · 1 shared drug class
- Amgen · 1 shared drug class
- Asan Medical Center · 1 shared drug class
- AstraZeneca · 1 shared drug class
- Beijing Friendship Hospital · 1 shared drug class
- Centre Hospitalier Universitaire Dijon · 1 shared drug class
- Centre Hospitalier Universitaire de Besancon · 1 shared drug class
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for SCRI Development Innovations, LLC:
- SCRI Development Innovations, LLC pipeline updates — RSS
- SCRI Development Innovations, LLC pipeline updates — Atom
- SCRI Development Innovations, LLC pipeline updates — JSON
Cite this brief
Drug Landscape (2026). SCRI Development Innovations, LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/scri-development-innovations-llc. Accessed 2026-06-09.